Erratum: Retraction to “Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells” (Lung Cancer (2009) 63(2) (227–234) (S0169500208003085) (10.1016/j.lungcan.2008.05.026));Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells

Lung Cancer

Volumn 63, Issue 2, 2009, Pages 227-234

  Fang, Kang ^a   Chen, Shih Ping ^a   Lin, Chia Wei ^a   Cheng, Wan Chun ^b   Huang, Hwei Tien ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF EDUCATION   (Taiwan)

Author keywords

Akt; Apoptosis; Ellipticine; Human non small cell lung cancer cells

Indexed keywords

ELLIPTICINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P53; WORTMANNIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; EPITHELIUM BASAL CELL; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 58049195157     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.08.010     Document Type: Erratum

References (34)

1. Hagg M., Berndtsson M., Mandic A., Zhou R., Shoshan M.C., and Linder S. Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 3 (2004) 489-497
2. Shi L.M., Myers T.G., Fan Y., O'Connor P.M., Paull K.D., Friend S.H., et al. Mining the national cancer institute anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 53 (1998) 241-251
3. Kenney S., Vistica D.T., Linden H., and Boyd M.R. Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem Pharmacol 49 (1995) 23-32
4. 1 phase by 9-hydroxyellipticine. Anticancer Res 19 (1999) 3099-3108
5. Kuo P.L., Hsu Y.L., Chang C.H., and Lin C.C. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223 (2005) 293-301
6. Kuo P.L., Hsu Y.L., Kuo Y.C., Chang C.H., and Lin C.C. The anti-proliferative inhibition of ellipticine in human breast MDA-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs 16 (2005) 789-795
7. Kuo Y.C., Kuo P.L., Hsu Y.L., Cho C.Y., and Lin C.C. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 78 (2006) 2550-2557
8. Zhang M., Fang X., Liu H., Wang S., and Yang D. Blockade of Akt activation in prostate cancer cells with a small molecule inhibitor 9-chloro-2-methylellipticinium acetate (CMEP). Biochem Pharmacol 73 (2007) 15-24
9. Pecq J.-B.L., Nguyen D.X., Gosse C., and Paoletti C. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. PNAS 71 (1974) 5078-5082
10. Stiborova M., Sejbal J., Borek-Dohalska L., Aimova D., Poljakova J., Forsterova K., et al. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64 (2004) 8374-8380
11. Sureau F., Moreau F., Millot J.M., Manfait M., Allard B., Aubard J., et al. Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid, in single cells. Biophys J 65 (1993) 1767-1774
12. Schwaller M.-A., Allard B., Lescot E., and Moreau F. Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria. J Biol Chem 270 (1995) 22709-22713
13. Tewey K.M., Chen G.L., Nelson E.M., and Liu L.F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259 (1984) 9182-9187
14. Chiu C.C., Lin C.H., and Fang K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 10 (2005) 643-650
15. Simbulan-Rosenthal C.M., Rosenthal D.S., Iyer S., Boulares H., and Smulson M.E. Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Mol Cell Biochem 193 (1999) 137-148
16. Peng Y., Li C., Chen L., Sebti S., and Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22 (2003) 4478-4487
17. Chiu C.C., Li C.H., Ung M.W., Fuh T.S., Chen W.L., and Fang K. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett 223 (2005) 249-258
18. Djuric Z., Everett C.K., and Valeriote F.A. DNA damage and cytotoxicity in L1210 cells by ellipticine and a structural analogue N-2-(diethylaminoethyl)-9-hydroxyellipticinium chloride. Cancer Res 52 (1992) 1515-1519
19. Kingma P.S., and Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J Biol Chem 272 (1997) 7488-7493
20. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 (2002) 335-346
21. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., and Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62 (2002) 1876-1883
22. VanderWeele D.J., Zhou R., and Rudin C.M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 3 (2004) 1605-1613
23. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 (2001) 3986-3997
24. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
25. Crowell J.A., and Steele V.E. Akt and the phosphatidylinositol 3-kinase/Akt pathway: important molecular targets for lung cancer prevention and treatment. J Natl Cancer Inst 95 (2003) 252-253
26. Testa J.R., and Bellacosa A. Akt plays a central role in tumorigenesis. PNAS 98 (2001) 10983-10985
27. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 212 (1997) 31515-31524
28. Feng J., Tamaskovic R., Yang Z., Brazil D.P., Merlo A., Hess D., et al. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 279 (2004) 35510-35517
29. Gottlieb T.M., Leal J.F., Seger R., Taya Y., and Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21 (2002) 1299-1303
30. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65 (2005) 3336-3346
31. Gozuacik D., and Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23 (2004) 2891-2906
32. Seglen P.O., and Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. PNAS 79 (1982) 1889-1892
33. Fujiwara K., Iwado E., Mills G.B., Sawaya R., Kondo S., and Kondo Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 31 (2007) 753-760
34. Sourbier C., Lindner V., Lang H., Agouni A., Schordan E., Danilin S., et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66 (2006) 5130-5142